Tesaro (Tesaro) Net Margin % : -212.87% (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Tesaro Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Tesaro's Net Income for the three months ended in Sep. 2018 was $-137.1 Mil. Tesaro's Revenue for the three months ended in Sep. 2018 was $64.4 Mil. Therefore, Tesaro's net margin for the quarter that ended in Sep. 2018 was -212.87%.

The historical rank and industry rank for Tesaro's Net Margin % or its related term are showing as below:

TSRO's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -162.84
* Ranked among companies with meaningful Net Margin % only.

Tesaro Net Margin % Historical Data

The historical data trend for Tesaro's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro Net Margin % Chart

Tesaro Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Net Margin %

Get a 7-Day Free Trial

-79,308.52

-864.45

-222.15

Tesaro Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Net Margin %	Get a 7-Day Free Trial															-17.71	-379.12	-327.32	-291.31	-212.87

Competitive Comparison of Tesaro's Net Margin %

For the Biotechnology subindustry, Tesaro's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tesaro's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tesaro's Net Margin % distribution charts can be found below:

* The bar in red indicates where Tesaro's Net Margin % falls into.

Tesaro Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Tesaro's Net Margin for the fiscal year that ended in Dec. 2017 is calculated as

Net Margin	=	Net Income (A: Dec. 2017 )	/	Revenue (A: Dec. 2017 )
	=	-496.126	/	223.326
	=	-222.15 %

Tesaro's Net Margin for the quarter that ended in Sep. 2018 is calculated as

Net Margin	=	Net Income (Q: Sep. 2018 )	/	Revenue (Q: Sep. 2018 )
	=	-137.088	/	64.399
	=	-212.87 %

Tesaro (NAS:TSRO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Tesaro Net Margin % Related Terms

Thank you for viewing the detailed overview of Tesaro's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tesaro (Tesaro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tesarobio.com

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Executives

Mary Lynne Hedley	director, officer: President & COO	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr.	officer: SVP & Chief Medical Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr	director, officer: Chief Executive Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson	officer: Exec. VP, CFO	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle	officer: Sr. VP, Chief Commercial Ofc	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg	director
Joseph L Farmer	officer: Sr VP, Gen Counsel & Secretary	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins	10 percent owner